Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 5540

1.

XRCC1 polymorphism and overall survival in ovarian cancer patients treated with platinum-based chemotherapy: A systematic review and MOOSE-compliant meta-analysis.

Zhang Z, Xiang Q, Mu G, Xie Q, Chen S, Zhou S, Hu K, Cui YM.

Medicine (Baltimore). 2018 Nov;97(45):e12996. doi: 10.1097/MD.0000000000012996. Review.

2.

Mechanism for the Decision of Ovarian Surface Epithelial Stem Cells to Undergo Neo-Oogenesis or Ovarian Tumorigenesis.

Xu J, Zheng T, Hong W, Ye H, Hu C, Zheng Y.

Cell Physiol Biochem. 2018;50(1):214-232. doi: 10.1159/000494001. Epub 2018 Oct 18. Review.

3.

Personalised medicine and population health: breast and ovarian cancer.

Narod SA.

Hum Genet. 2018 Oct;137(10):769-778. doi: 10.1007/s00439-018-1944-6. Epub 2018 Oct 17. Review.

PMID:
30328515
4.

The role of vitamin D in ovarian cancer: epidemiology, molecular mechanism and prevention.

Guo H, Guo J, Xie W, Yuan L, Sheng X.

J Ovarian Res. 2018 Aug 29;11(1):71. doi: 10.1186/s13048-018-0443-7. Review.

5.

Ovarian yolk sac tumor in postmenopausal females: A case series and a literature review.

Wang Y, Yang J, Yu M, Cao D, Zhang Y, Zong X, Shen K.

Medicine (Baltimore). 2018 Aug;97(33):e11838. doi: 10.1097/MD.0000000000011838. Review.

6.

The Prognostic Value of 18F-FDG PET/CT in Monitoring Chemotherapy in Ovarian Cancer Both at Initial Diagnosis and at Recurrent Disease.

Rubello D, Marzola MC, Colletti PM.

Clin Nucl Med. 2018 Oct;43(10):735-738. doi: 10.1097/RLU.0000000000002227. Review.

PMID:
30106857
7.

Prognostic significance of β-catenin expression in patients with ovarian cancer: A meta-analysis.

Long H, Li G, Wen X, Lv Y, Zhang M, Wei Y, Xie W, Zhong P, Pang L.

Gene. 2018 Dec 15;678:270-279. doi: 10.1016/j.gene.2018.08.047. Epub 2018 Aug 10. Review.

PMID:
30103006
8.

Ovarian cancer screening-ultrasound; impact on ovarian cancer mortality.

Kamal R, Hamed S, Mansour S, Mounir Y, Abdel Sallam S.

Br J Radiol. 2018 Oct;91(1090):20170571. doi: 10.1259/bjr.20170571. Epub 2018 Sep 4. Review.

PMID:
30102555
9.

Clinical benefit of controversial first line systemic therapies for advanced stage ovarian cancer - ESMO-MCBS scores.

Broekman KE, Jalving M, van Tinteren H, Sessa C, Reyners AKL.

Cancer Treat Rev. 2018 Sep;69:233-242. doi: 10.1016/j.ctrv.2018.06.008. Epub 2018 Jun 18. Review.

10.

Does B7-H4 expression correlate with clinicopathologic characteristics and survival in ovarian cancer?: A systematic review and PRISMA-compliant meta-analysis.

Ye Y, Wang JJ, Li SL, Wang SY, Jing FH.

Medicine (Baltimore). 2018 Aug;97(32):e11821. doi: 10.1097/MD.0000000000011821. Review.

11.

MicroRNA-200 and microRNA-30 family as prognostic molecular signatures in ovarian cancer: A meta-analysis.

Shi M, Mu Y, Zhang H, Liu M, Wan J, Qin X, Li C.

Medicine (Baltimore). 2018 Aug;97(32):e11505. doi: 10.1097/MD.0000000000011505. Review.

12.

Altered long noncoding RNAs and survival outcomes in ovarian cancer: A systematic review and meta-analysis (PRISMA Compliant).

Ning L, Hu YC, Wang S, Lang JH.

Medicine (Baltimore). 2018 Aug;97(32):e11481. doi: 10.1097/MD.0000000000011481. Review.

13.

Surgical prevention strategies in ovarian cancer.

Mallen A, Soong TR, Townsend MK, Wenham RM, Crum CP, Tworoger SS.

Gynecol Oncol. 2018 Oct;151(1):166-175. doi: 10.1016/j.ygyno.2018.08.005. Epub 2018 Aug 4. Review.

PMID:
30087058
14.

Management of newly diagnosed or recurrent ovarian cancer.

Matulonis UA.

Clin Adv Hematol Oncol. 2018 Jun;16(6):426-437. Review.

PMID:
30067614
15.

Protease-Activated Receptor 1 as Therapeutic Target in Breast, Lung, and Ovarian Cancer: Pepducin Approach.

Covic L, Kuliopulos A.

Int J Mol Sci. 2018 Jul 31;19(8). pii: E2237. doi: 10.3390/ijms19082237. Review.

16.

Do genetic polymorphisms of the vitamin D receptor contribute to breast/ovarian cancer? A systematic review and network meta-analysis.

Li J, Li B, Jiang Q, Zhang Y, Liu A, Wang H, Zhang J, Qin Q, Hong Z, Li BA.

Gene. 2018 Nov 30;677:211-227. doi: 10.1016/j.gene.2018.07.070. Epub 2018 Jul 29. Review.

PMID:
30059751
17.

One-Carbon Metabolism: Biological Players in Epithelial Ovarian Cancer.

Rizzo A, Napoli A, Roggiani F, Tomassetti A, Bagnoli M, Mezzanzanica D.

Int J Mol Sci. 2018 Jul 19;19(7). pii: E2092. doi: 10.3390/ijms19072092. Review.

18.

Novel targeted therapies in ovarian and uterine carcinosarcomas.

Han C, Altwerger G, Menderes G, Haines K, Feinberg J, Lopez S, Manzano A, Varughese J, Santin AD.

Discov Med. 2018 Jun;25(140):309-319. Review.

19.

Recent Progress in Gene Therapy for Ovarian Cancer.

Áyen Á, Jiménez Martínez Y, Marchal JA, Boulaiz H.

Int J Mol Sci. 2018 Jun 30;19(7). pii: E1930. doi: 10.3390/ijms19071930. Review.

20.

Risk reduction of endometrial and ovarian cancer after bisphosphonates use: A meta-analysis.

Zhang XS, Zhang YM, Li B, Fan B, Zhao Y, Yang SJ.

Gynecol Oncol. 2018 Sep;150(3):509-514. doi: 10.1016/j.ygyno.2018.06.012. Epub 2018 Jun 28. Review.

PMID:
29960711

Supplemental Content

Loading ...
Support Center